Circio Holding ASA (FRA:TA50)
€ 0.0006 0 (0%) Market Cap: 3.16 Mil Enterprise Value: 5.87 Mil PE Ratio: 0.98 PB Ratio: 0 GF Score: 1/100

Targovax ASA Corporate Analyst Meeting Transcript

Feb 18, 2021 / 01:30PM GMT
Release Date Price: €20.33 (-1.48%)
Ã;ystein Soug
Targovax ASA - CEO

Ladies and gentlemen, please let me welcome you to our Capital Markets Day, our key opinion leader event and our fourth quarter 2020 presentation. My name is Ãystein Soug, and I'm the CEO of Targovax.

We have a great program for you for the next couple of hours. Today, its main focus is going to be on the ONCOS-102 development program. And we have people in 4 different countries and hopefully, the technicals will work out well.

We'll start with an update on our latest PD-1 refractory melanoma trial in combination with KEYTRUDA. And for that, we have invited our principal investigator from that trial, Dr. Alexander Shoushtari. After Dr. Shoushtari's presentation, our Chief Medical Officer, Magnus Jäderberg, will lay out the plans that we have for further steps in melanoma, namely a trial intended to create data to support registration of ONCOS-102. He will also touch upon the other trials that we are going in the company, and we'll also put it all into context for you.

After a short break, Chief Scientific Officer, Victor

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot